June 05, 2026
IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery.
February 26, 2026
IRhythm Technologies investors urged a California federal judge Thursday to certify a class that bought 30 million shares while the digital healthcare company allegedly jacked its stock price with false and misleading statements about a heart-event monitoring device, saying the U.S. Supreme Court's 2021 Goldman price impact ruling doesn't apply.
November 10, 2025
Heart monitor maker iRhythm Technologies cannot get an early win in a proposed investor class action alleging it made misleading disclosures about one of its devices, a San Francisco federal judge has determined.
November 04, 2025
Investors in digital healthcare company iRhythm Technologies are seeking certification of a class that bought shares of the company over a roughly two-year period during which it allegedly concealed issues with its Zio AT heart-event monitoring device.
June 04, 2025
A California federal judge has trimmed a class action accusing digital healthcare company iRhythm Technologies of making false and misleading statements about its heart-event monitoring device, finding that the suit does not plausibly plead knowledge of wrongdoing for most individual defendants, among other things.